Hi Rebekah,
Im assuming you watched the webinar.
My take is that once they have more confirmed evidence, they will def put forward a case too MJFF. As stated in the early stages of parkinsons and MSA, it is too hard to tell the difference between the two, as they affect similar parts of the brain.
Given the recent results were to show case the results for the FDA, and having these results even further supported by positive results on completion of the 201 study, the FDA will def fast track ATH434.
Once results are in and further results return from the 202 study, things will move very fast.
Ann: Positive Interim Data from ATH434-202 Phase 2 Clinical Trial, page-158
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(11.1%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.4¢ | $1.528K | 317.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 102 | 97511267 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 31179254 | 15 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |